If the off-label use of GLP-1s for type 1 diabetes becomes so prevalent as to be impossible to ignore, the FDA might mandate the companies to go and do these studies, says Garg
It has received warning letters from the FDA, although the last one was closed out in May 2022, which means the FDA found that it had addressed outstanding issues
Among participants who escalated from placebo to 1.6 mg or 2.4 mg weekly berobenatide, weight loss was 15.9% to 16.8% over 32 weeks in the open-label extension, according to the results
From reducing the risk of chronic diseases to increasing energy levels, the benefits of good health habits are numerous and well worth the effort
High-sensitivity techniques, such as Peng et al.s (2024) UPLC-QTOF-MS-based profiling of TCM constituents, address key analytical challenges in pharmacokinetics and formulation, offering tools applicable to GPS research for metabolite quantification and characterization (Peng et al., 2024)
Best taken on an empty stomach, at least 20 minutes before meals